Observatory of Immunological Thrombopenic Purpura in the Brest Region
NCT ID: NCT06556888
Last Updated: 2024-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2019-06-20
2039-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research of Predictive Factors to Immune Thrombopenic Purpura
NCT01648556
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
NCT04070599
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
NCT04056507
Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)
NCT06481332
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
NCT00331357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
UHB is the regional reference center (competence center) on hemorrhagic diseases.
Dr Pan-Petesch, who is responsible of the local competence center, is affiliated to the national sector of auto-immune cytopenias CERECAI-MARIH).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients Under guardianship
* Patients without national social security
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brigitte Pan-Petesch, MD
Role: PRINCIPAL_INVESTIGATOR
UHB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hematology Department - Institute of Oncology and Hematology, University Hospital of Brest
Brest, Brittany Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29BRC19.0089
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.